推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 據(jù)最新消息，孟山都拒絕了拜耳的620億美元收購(gòu)要約，稱(chēng)公司值得獲得更高報(bào)價(jià)，但表示對(duì)進(jìn)一步洽談此項(xiàng)交易持開(kāi)放態(tài)度。
根據(jù)公司網(wǎng)站消息，孟山都稱(chēng)“其董事會(huì)一致認(rèn)為拜耳股份公司的提案不完全且報(bào)價(jià)不足，但愿意繼續(xù)進(jìn)行有建設(shè)性的對(duì)話，以評(píng)估能否達(dá)成一項(xiàng)交易以實(shí)現(xiàn)孟山都股東最大利益?！?/p>
孟山都首席執(zhí)行官及總裁Hugh Grant表示：“我們相信一個(gè)整合策略可能為增長(zhǎng)和更廣泛的社會(huì)帶來(lái)的巨大利處，我們一直也很尊重拜耳公司。然而目前的要約明顯低估了我們公司，并也無(wú)法充分解決或保障并購(gòu)存在的潛在融資風(fēng)險(xiǎn)及監(jiān)管審查風(fēng)險(xiǎn)?！?/p>
孟山都股東Davenport Capital Management LLC的研究部負(fù)責(zé)人Joel Ray表示，關(guān)鍵問(wèn)題在于公司現(xiàn)在并未處于財(cái)務(wù)困境，而是目前處于農(nóng)業(yè)周期循環(huán)的底部，這最終導(dǎo)致該公司因此而估值過(guò)低。孟山都對(duì)探討并購(gòu)交易仍持開(kāi)放態(tài)度，因其看到合并的策略性理由。
拜耳的一名發(fā)言人表示公司將審閱并考慮孟山都的回應(yīng)。
